K2 HealthVentures
VC Fund
Boston, United States
K2 HealthVentures is an alternative investment firm.
- Total investments:
- 57
- Last investment:
- Lead investor:
- 58%
Last updated:
For AI agents: llms.txt
Industries K2 HealthVentures invests in
Stages K2 HealthVentures invests in
Countries K2 HealthVentures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anup Arora
|
|||
Nimesh Shah
|
|||
Austin Sherwindt
|
|||
Derek Abel
|
|||
Emily Pettycrew
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 31 (54%)
- Biotechnology 30 (53%)
- Medical 20 (35%)
- Pharmaceutical 13 (23%)
- Therapeutics 11 (19%)
Stage
- Post-IPO Debt 16 (28%)
- Debt Financing 14 (25%)
- Private Equity 6 (11%)
- Series B 4 (7%)
- Venture - Series Unknown 4 (7%)
Country
- United States 46 (81%)
- Singapore 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anup Arora
Founder, Managing Director & CIO
|
Founder, Managing Director & CIO | Total investments: 12 | Find email | |
|
Nimesh Shah
Managing Director
|
Managing Director | Total investments: 14 | Find email | |
|
Austin Sherwindt
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
|
Derek Abel
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
Emily Pettycrew
Vice President of Finance and Operations
|
Vice President of Finance and Operations | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Stealth BioTherapeutics
|
Stealth is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. | $95M / Debt Financing / Jul 14, 2026 | |
Cartesian Therapeutics
|
Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company developing novel cell and gene immunotherapies to treat cancer and autoimmune diseases. | $50M / Post-IPO Debt / May 26, 2026 | |
Honest Health
|
Honest is purpose-built to improve member satisfaction, improve care, and reduce costs for people with Medicare by integrating payer and provider functions to support patients. | $140M / Venture - Series Unknown / Feb 26, 2026 | |
Zarminali Health
|
Zarminali Health transforms pediatric care by building multispecialty pediatric group that provides modern, seamlessly coordinated care. | $110M / Series A / Jan 21, 2026 | |
Kandu Health
|
Kandu Health is a tech-enabled healthcare company that provides stroke recovery training, stroke detection research, and education services. | Venture - Series Unknown / Jan 12, 2026 | |
Apella Technology
|
Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California. | $80M / Series B / Jan 07, 2026 | |
Phil
|
Phil offers a technology-driven platform that simplifies medication access for retail and specialty-lite brands. Its solutions aim to improve patient outcomes and drive commercial success by streamlining the script journey. PhilRx provides features such as a digital hub, advanced prior authorization, an integrated pharmacy network, and end-to-endvisibility and insights. | $60M / Debt Financing / Jul 08, 2025 | |
Umoja Biopharma
|
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer. | $100M / Series C / Jan 14, 2025 | |
Evergreen Nephrology
|
Evergreen helps nephrologists focus on the right patients at the right time across the full care spectrum. They create strategic partnerships to empower nephrologists with financial backing. As part of that partnership, we provide nephrologists with the best-in-class interdisciplinary clinical resources, analytical insight and tools, and servicesto patients. | $130M / Venture - Series Unknown / Jan 07, 2025 | |
HarmonyCares
|
USMM is a family of companies dedicated to providing high-quality, coordinated healthcare in the home. USMM has also developed and owns several allied health assets, which assist in the provision of home-based primary care and furthers the value and efficiency of house call medicine. | $200M / Private Equity / Jul 08, 2024 | |
| See all 57 investments → | |||
Co-Investors
Oak HC/FT
6 deals together
General Catalyst
3 deals together
Rubicon Founders
3 deals together
8VC
2 deals together
CareCentrix
2 deals together
Cormorant Asset Management
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does K2 HealthVentures invest in?
K2 HealthVentures invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Debt and Debt Financing stage. Most of the 57 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact K2 HealthVentures?
Public channels for K2 HealthVentures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at K2 HealthVentures?
The team at K2 HealthVentures includes Anup Arora (Founder, Managing Director & CIO), Nimesh Shah (Managing Director) and Austin Sherwindt (Managing Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
